Private Trust Company’s Mangoceuticals MGRX Stock Holding History

Private Trust Company’s Portfolio MGRX Stock Details MGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-100	Closed	-$2.75K	–	2361
2023 Q2	$2.75K	Buy	+100	New	+$1.97K	﹤0.01%	2050

Other funds holding MGRX

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

DGAM

Desjardins Global Asset Management Montreal, Quebec, Canada $930M AUM 31.76% 1-Year Est. Return

Vanguard Capital Wealth Advisors Denver, Colorado $148M AUM 91.21% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

MCG

McCollum Christoferson Group Amherst, New York $341M AUM 15.01% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

IAA

Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Private Trust Company's MGRX Position: Q3 2023 in Review

Private Trust Company sold out of Mangoceuticals (MGRX) in Q3 2023, closing a stake of 100 shares — an estimated $2.75K sold.

Private Trust Company first reported a position in MGRX in Q2 2023 and held it in 1 quarter. The position peaked at $2.75K in Q2 2023. 9 funds tracked by Wall St. Rank hold MGRX as of Q3 2023.

Private Trust Company reported no remaining Mangoceuticals position as of Q3 2023 after selling out during the quarter.
Private Trust Company sold 100 Mangoceuticals shares in Q3 2023, an estimated $2.75K.
Private Trust Company first reported a position in Mangoceuticals in Q2 2023 and held it in 1 quarter.
Private Trust Company's Mangoceuticals position peaked at $2.75K in Q2 2023.
9 funds tracked by Wall St. Rank held Mangoceuticals as of Q3 2023.

Based on Private Trust Company's 13F filing for Q3 2023, filed 18 Oct 2023.